1
|
Abdalla AL, Guajardo-Contreras G, Mouland AJ. A Canadian Survey of Research on HIV-1 Latency-Where Are We Now and Where Are We Heading? Viruses 2024; 16:229. [PMID: 38400005 PMCID: PMC10891605 DOI: 10.3390/v16020229] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2024] [Revised: 01/26/2024] [Accepted: 01/30/2024] [Indexed: 02/25/2024] Open
Abstract
Worldwide, almost 40 million people are currently living with HIV-1. The implementation of cART inhibits HIV-1 replication and reduces viremia but fails to eliminate HIV-1 from latently infected cells. These cells are considered viral reservoirs from which HIV-1 rebounds if cART is interrupted. Several efforts have been made to identify these cells and their niches. There has been little success in diminishing the pool of latently infected cells, underscoring the urgency to continue efforts to fully understand how HIV-1 establishes and maintains a latent state. Reactivating HIV-1 expression in these cells using latency-reversing agents (LRAs) has been successful, but only in vitro. This review aims to provide a broad view of HIV-1 latency, highlighting Canadian contributions toward these aims. We will summarize the research efforts conducted in Canadian labs to understand the establishment of latently infected cells and how this informs curative strategies, by reviewing how HIV latency is established, which cells are latently infected, what methodologies have been developed to characterize them, how new compounds are discovered and evaluated as potential LRAs, and what clinical trials aim to reverse latency in people living with HIV (PLWH).
Collapse
Affiliation(s)
- Ana Luiza Abdalla
- HIV-1 RNA Trafficking Laboratory, Lady Davis Institute at the Jewish General Hospital, Montreal, QC H3T 1E2, Canada; (A.L.A.); (G.G.-C.)
- Department of Microbiology and Immunology, McGill University, Montreal, QC H3A 2B4, Canada
| | - Gabriel Guajardo-Contreras
- HIV-1 RNA Trafficking Laboratory, Lady Davis Institute at the Jewish General Hospital, Montreal, QC H3T 1E2, Canada; (A.L.A.); (G.G.-C.)
- Department of Medicine, McGill University, Montreal, QC H4A 3J1, Canada
| | - Andrew J. Mouland
- HIV-1 RNA Trafficking Laboratory, Lady Davis Institute at the Jewish General Hospital, Montreal, QC H3T 1E2, Canada; (A.L.A.); (G.G.-C.)
- Department of Microbiology and Immunology, McGill University, Montreal, QC H3A 2B4, Canada
- Department of Medicine, McGill University, Montreal, QC H4A 3J1, Canada
| |
Collapse
|
4
|
Lin Q, Deng B, Rui J, Guo SB, Hu Q, Chen Q, Tang C, Zhou L, Zhao Z, Lin S, Zhu Y, Yang M, Wang Y, Xu J, Liu X, Yang T, Li P, Li Z, Luo L, Liu W, Liu C, Huang J, Yao M, Nong M, Nong L, Wu J, Luo N, Chen S, Frutos R, Yang S, Li Q, Cui JA, Chen T. Epidemiological Characteristics and Transmissibility of Human Immunodeficiency Virus in Nanning City, China, 2001-2020. Front Public Health 2022; 9:689575. [PMID: 35004557 PMCID: PMC8733253 DOI: 10.3389/fpubh.2021.689575] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2021] [Accepted: 11/11/2021] [Indexed: 11/30/2022] Open
Abstract
Background: Human immunodeficiency virus (HIV) is a single-stranded RNA virus that can weaken the body's cellular and humoral immunity and is a serious disease without specific drug management and vaccine. This study aimed to evaluate the epidemiologic characteristics and transmissibility of HIV. Methods: Data on HIV follow-up were collected in Nanning City, Guangxi Zhuang Autonomous, China. An HIV transmission dynamics model was built to simulate the transmission of HIV and estimate its transmissibility by comparing the effective reproduction number (Reff) at different stages: the rapid growth period from January 2001 to March 2005, slow growth period from April 2005 to April 2011, and the plateau from May 2011 to December 2019 of HIV in Nanning City. Results: High-risk areas of HIV prevalence in Nanning City were mainly concentrated in suburbs. Furthermore, high-risk groups were those of older age, with lower income, and lower education levels. The Reff in each stage (rapid growth, slow growth, and plateau) were 2.74, 1.62, and 1.15, respectively, which suggests the transmissibility of HIV in Nanning City has declined and prevention and control measures have achieved significant results. Conclusion: Over the past 20 years, the HIV incidence in Nanning has remained at a relatively high level, but its development trend has been curbed. Transmissibility was reduced from 2.74 to 1.15. Therefore, the prevention and treatment measures in Nanning City have achieved significant improvement.
Collapse
Affiliation(s)
- Qian Lin
- Development Planning Office, Guangxi Medical University, Nanning, China
| | - Bin Deng
- Department of Science and Technology, School of Public Health, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, Xiamen University, Xiamen, China
| | - Jia Rui
- Department of Science and Technology, School of Public Health, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, Xiamen University, Xiamen, China
| | - Song-Bai Guo
- Department of Mathematics and Data Science, School of Science, Beijing University of Civil Engineering and Architecture, Beijing, China
| | - Qingqing Hu
- Division of Public Health, School of Medicine, University of Utah, 201 Presidents Circle, Salt Lake, UT, United States
| | - Qiuping Chen
- Laboratory Intertryp CIRAD/IRD, Université de Montpellier, Montpellier, France.,Department of Medical Insurance Office, Xiang'an Hospital of Xiamen University, Xiamen, China
| | - Chi Tang
- Division of Director's Office, Nanning Municipal Health Commission, Nanning, China
| | - Lina Zhou
- Department of Nephrology, The Second Hospital of Xiamen Medical College, Xiamen, China
| | - Zeyu Zhao
- Development Planning Office, Guangxi Medical University, Nanning, China.,Laboratory Intertryp CIRAD/IRD, Université de Montpellier, Montpellier, France
| | - Shengnan Lin
- Department of Science and Technology, School of Public Health, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, Xiamen University, Xiamen, China
| | - Yuanzhao Zhu
- Department of Science and Technology, School of Public Health, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, Xiamen University, Xiamen, China
| | - Meng Yang
- Department of Science and Technology, School of Public Health, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, Xiamen University, Xiamen, China
| | - Yao Wang
- Department of Science and Technology, School of Public Health, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, Xiamen University, Xiamen, China
| | - Jingwen Xu
- Department of Science and Technology, School of Public Health, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, Xiamen University, Xiamen, China
| | - Xingchun Liu
- Department of Science and Technology, School of Public Health, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, Xiamen University, Xiamen, China
| | - Tianlong Yang
- Department of Science and Technology, School of Public Health, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, Xiamen University, Xiamen, China
| | - Peihua Li
- Department of Science and Technology, School of Public Health, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, Xiamen University, Xiamen, China
| | - Zhuoyang Li
- Department of Science and Technology, School of Public Health, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, Xiamen University, Xiamen, China
| | - Li Luo
- Department of Science and Technology, School of Public Health, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, Xiamen University, Xiamen, China
| | - Weikang Liu
- Department of Science and Technology, School of Public Health, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, Xiamen University, Xiamen, China
| | - Chan Liu
- Department of Science and Technology, School of Public Health, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, Xiamen University, Xiamen, China
| | - Jiefeng Huang
- Department of Science and Technology, School of Public Health, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, Xiamen University, Xiamen, China
| | - Min Yao
- Department of STD and AIDS Prevention and Treatment, Nanning Center for Disease Control and Prevention, Nanning, China
| | - Mengni Nong
- Department of STD and AIDS Prevention and Treatment, Nanning Center for Disease Control and Prevention, Nanning, China
| | - Liping Nong
- Department of STD and AIDS Prevention and Treatment, Nanning Center for Disease Control and Prevention, Nanning, China
| | - Jinglan Wu
- Department of STD and AIDS Prevention and Treatment, Nanning Center for Disease Control and Prevention, Nanning, China
| | - Na Luo
- Department of STD and AIDS Prevention and Treatment, Nanning Center for Disease Control and Prevention, Nanning, China
| | - Shihai Chen
- Division of Director's Office, Nanning Municipal Health Commission, Nanning, China
| | - Roger Frutos
- Department of Medical Insurance Office, Xiang'an Hospital of Xiamen University, Xiamen, China
| | - Shixiong Yang
- Department of STD and AIDS Prevention and Treatment, Nanning Center for Disease Control and Prevention, Nanning, China
| | - Qun Li
- Department of Health Emergency, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Jing-An Cui
- Department of Mathematics and Data Science, School of Science, Beijing University of Civil Engineering and Architecture, Beijing, China
| | - Tianmu Chen
- Department of Science and Technology, School of Public Health, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, Xiamen University, Xiamen, China
| |
Collapse
|